Rapport Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Rapport Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($26.93M) | Nov 6, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($26.73M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($26.73M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($24.06M) | Nov 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($24.06M) | May 8, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($24.06M) | Aug 7, 2025 |
| Q3 | 2025 | Dec 31, 2024 | ($78.30M) | Nov 6, 2025 |
| Q2 | 2025 | Dec 31, 2024 | ($78.30M) | Aug 7, 2025 |
| Q1 | 2025 | Dec 31, 2024 | ($78.30M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($17.54M) | Nov 6, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($18.12M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($18.12M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($22.67M) | Nov 6, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($22.67M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($22.67M) | May 8, 2025 |
| Q3 | 2024 | Dec 31, 2023 | ($34.80M) | Nov 7, 2024 |
| Q2 | 2024 | Dec 31, 2023 | ($34.80M) | Aug 8, 2024 |
| Q3 | 2024 | Sep 30, 2023 | ($8.71M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($6.41M) | Aug 8, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($6.41M) | Nov 7, 2024 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($29.99M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($29.50M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($27.11M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($21.64M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($20.80M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($17.09M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($9.56M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($6.63M) | Aug 8, 2024 |